Industry News
Keith Williams retires as Proteome director, remains as consultant
Proteome Systems (ASX:PXL) founder Dr Keith Williams is no longer a director of the company he established in 1999, following his decision to withdraw his nomination for re-election at yesterday's AGM. [ + ]
French order for Relenza triples cumulative global sales
A French government announcement that it would increase its pandemic stockpile of Relenza from 200,000 units to 9 million units over the next two years has sent shares in Melbourne-based Biota Holding's (ASX:BTA) up by more than 20 per cent. [ + ]
Solbec earns orphan drug status for carcinoma treatment
Solbec Pharmaceuticals (ASX:SBP) has received orphan drug designation from the US Food and Drug Administration for its lead anti-cancer compound Coramsine for the treatment of metastatic renal cell carcinoma (mRCC). [ + ]
Incoming Mayne Pharma CEO sees growth through acquisitions
The incoming chief of Mayne Pharma, the global injectable drugs business soon to emerge from the break-up of Mayne Group (ASX:MAY), said growth would have to come from acquisitions and expansion into new areas. [ + ]
UQ team helps tap into the alcoholic brain
Researchers at the University of Queensland have discovered fundamental differences in patterns of gene expression in alcoholic versus normal brains. [ + ]
Probiomics nets govt grant
Probiomics (ASX:PCC), formerly VRI BioMedical, has received an AusIndustry Commercial Ready grant for the next stage of its molecular discovery program. [ + ]
Ventracor, Heartware settle patent dispute
Artificial heart firms Ventracor (ASX:VCR) and HeartWare (ASX:HTW) have settled a year-long patent dispute. [ + ]
Mimotopes to team with Genzyme in peptide supply deal
PharmAust (ASX:PAA) subsidiary Mimotopes will team up with US-based Genzyme Pharmaceuticals in a strategic alliance to provide peptide products and services to both companies' customers globally. [ + ]
TGR/Nanyang deal
TGR BioSciences has received an equity investment from the Nanyang Innovation Fund managed by Nanyang Ventures (Nanyang). Nanyang will progressively invest up to $3 million into TGR, subject to TGR meeting certain milestones.
[ + ]Avexa and CSIRO to collaborate
Melbourne-based Avexa (ASX:AVX) and the CSIRO have entered into a collaboration deal to discover new drugs for the treatment of human viral diseases. [ + ]
AtCor lists on ASX ahead of schedule
Shares in AtCor Medical (ASX:ACG), the developer and marketer of a device to measure cardiovascular function, began trading on the Australian Stock Exchange today at $0.65, 7.5 per cent above its issue price of $0.50. [ + ]
Pharmaxis sets US share price at $33
Drug developer Pharmaxis (ASX:PXS) has set the pricing of an underwritten public offering of 1,300,000 American Depositary Shares at a price of US$24.16 (AUD$33) per ADS. [ + ]
Dr Findlay's DNA casebook provides a Ripper yarn
Could an Australian gene-test company's uniquely sensitive new DNA fingerprinting technique finally finger history's most notorious serial murderer, London's Jack the Ripper? [ + ]
Tissue Therapies hopes new model can eliminate need for animal tests
If beauty is skin deep, the latest wrinkle from Brisbane biotech Tissue Therapies (ASX:TIS) should hold deep allure for cosmetics companies -- the company's researchers have developed a live-skin model with the same structure and properties as human skin. [ + ]
Portland Orthopaedics to raise up to $5 million, list on ASX
Hip replacement specialist Portland Orthopaedics has joined the growing list of companies who have lodged a prospectus to list on the ASX before Christmas. [ + ]
